Effects on renal sympathetic axons in dog of acute 6-hydroxydopamine treatment in combination with selective neuronal uptake inhibitors

Drug resistant hypertension – no simple way out

Hypertension poses growing challenge for health policy-makers and doctors worldwide. Recently published results of Symplicity-III trial (HTN-3), the first blinded, randomized, multicenter study on the efficacy of renal denervation for the treatment of resistant hypertension did not show a significant reduction of BP in patients with resistant hypertension 6 months after renal-artery denervation, as compared with controls. In this paper we review clinical and experimental studies on renal denervation. In order to identify causes of inconsistent results in renal denervation studies we look at basic science support for renal denervation and at designs of clinical trials.

The 6-Hydroxydopamine model of parkinson’s disease

The neurotoxin 6-hydroxydopamine (6-OHDA) continues to constitute a valuable topical tool used chiefly in modeling Parkinson's disease in the rat. The classical method of intracerebral infusion of 6-OHDA involving a massive destruction of nigrostriatal dopaminergic neurons, is largely used to investigate motor and biochemical dysfunctions in Parkinson's disease. Subsequently, more subtle models of partial dopaminergic degeneration have been developed with the aim of revealing finer motor deficits. The present review will examine the main features of 6-OHDA models, namely the mechanisms of neurotoxin-induced neurodegeneration as well as several behavioural deficits and motor dysfunctions, including the priming model, modeled by this means. An overview of the most recent morphological and biochemical findings obtained with the 6-OHDA model will also be provided, particular attention being focused on the newly investigated intracellular mechanisms at the striatal level (e.g., A(2A) and NMDA receptors, PKA, CaMKII, ERK kinases, as well as immediate early genes, GAD67 and peptides). Thanks to studies performed in the 6-OHDA model, all these mechanisms have now been hypothesised to represent the site of pathological dysfunction at cellular level in Parkinson's disease.

Time course and mechanism of myocardial catecholamine release during transient ischemia in vivo

BACKGROUND

Elevated concentrations of norepinephrine (NE) have been observed in ischemic myocardium. We investigated the magnitude and mechanism of catecholamine release in the myocardial interstitial fluid (MIF) during ischemia and reperfusion in vivo through the use of microdialysis.

METHODS AND RESULTS

In 9 anesthetized pigs, interstitial catecholamine concentrations were measured in the perfusion areas of the left anterior descending coronary artery (LAD) and the left circumflex coronary artery. After stabilization, the LAD was occluded for 60 minutes and reperfused for 150 minutes. During the final 30 minutes, tyramine (154 nmol. kg(-1). min(-1)) was infused into the LAD. During LAD occlusion, MIF NE concentrations in the ischemic region increased progressively from 1. 0+/-0.1 to 524+/-125 nmol/L. MIF concentrations of dopamine and epinephrine rose from 0.4+/-0.1 to 43.9+/-9.5 nmol/L and from <0.2 (detection limit) to 4.7+/-0.7 nmol/L, respectively. Local uptake-1 blockade attenuated release of all 3 catecholamines by >50%. During reperfusion, MIF catecholamine concentrations returned to baseline within 120 minutes. At that time, the tyramine-induced NE release was similar to that seen in nonischemic control animals despite massive infarction. Arterial and MIF catecholamine concentrations in the left circumflex coronary artery region remained unchanged.

CONCLUSIONS

Myocardial ischemia is associated with a pronounced increase of MIF catecholamines, which is at least in part mediated by a reversed neuronal reuptake mechanism. The increase of MIF epinephrine implies a (probably neuronal) cardiac source, whereas the preserved catecholamine response to tyramine in postischemic necrotic myocardium indicates functional integrity of sympathetic nerve terminals.

A study of the neuronal and non-neuronal stores of dopamine in rat and rabbit kidney

The present study has examined the effects of 6-hydroxydopamine (6-OHDA) alone and in combination with pargyline, desipramine and GBR 12909 and denervation as induced by occlusion of the renal artery (RAO) on the endogenous dopamine (DA) and noradrenaline (NA) contents in rat and rabbit renal tissues; the effects of chemical denervation on catecholamine levels in the left ventricle were also studied. In rat and rabbit renal medulla and rat renal cortex, 6-OHDA and pargyline plus 6-OHDA selectively reduced NA (85-92% reduction) without a parallel decrease in DA tissue content (19-27% reduction). This 6-OHDA- and pargyline plus 6-OHDA-insensitive DA pool was found to be resistant to denervation as induced by RAO. The NA-depleting effect of 6-OHDA in these renal areas was found to be prevented by the previous administration of desipramine, but not with that of GBR 12909. In the rabbit renal cortex, 6-OHDA selectively reduced NA (90% reduction) without a parallel depletion of DA (20% reduction); previous treatment with pargyline abolished this selectivity. Again, only desipramine, but not GBR 12909, was found to prevent the NA and DA depleting effect of 6-OHDA in the rabbit renal cortex. Denervation induced by RAO was also found to produce a parallel depletion of DA and NA tissue levels in this renal area. In the left ventricle, 6-OHDA alone or in combination with pargyline produced a parallel depletion of DA and NA tissue levels (79-88% reduction) in both species. These results provide evidence against the presence of independent dopaminergic neurones in rat and rabbit kidney and suggest that in rat and rabbit renal medulla and rat renal cortex most of DA is stored in a non-neuronal compartment; in rabbit renal cortex some of the DA appears to be located in noradrenergic neurones, in a store different from that which contains NA.

Further evidence for a dopaminergic involvement in the renal action of centrally administered atrial natriuretic peptide in rats

Intracerebroventricular (ICV) administration of atrial natriuretic peptide (ANP) induces an increase of urinary volume and sodium excretion in conscious male hydrated rats. The involvement of brain dopaminergic neurones in the ICV-ANP renal action was investigated. Diuretic and natriuretic action of ANP was prevented by inhibition of tyrosine hydroxylase activity with alpha-methyl-p-tyrosine treatment and was absent following selective central dopaminergic denervation with ICV administration of 6-hydroxydopamine in combination with desmethylimipramine (IP). Our results suggest that ANP acts centrally, at least in part, via an interaction with endogenous dopamine neurones.

A functional role for renal dopaminergic nerves in the dog

1. Efferent renal nerve stimulation at 5 Hz causes secretion of both dopamine (DA) and noradrenaline (NA) into renal venous plasma. DA comprises about 8% of the total catecholamine overflow; by contrast, DA efflux into femoral venous plasma following stimulation of the lumbar sympathetic nerves is 1% or less of total catecholamine. 2. Intact, but not denervated, kidneys of volume-loaded dogs also secrete both dopamine (DA) and noradrenaline (NA) into renal venous blood at rest, but the DA:NA ratio is considerably higher than that evoked by nerve stimulation. 3. Acute animal treatment with 6-hydroxydopamine (6-OHDA) abolishes stimulus-evoked catecholamine overflow and the usual fall in glomerular filtration and sodium and water excretion that accompanies renal nerve activation. 4. When 6-OHDA is administered in the presence of a selective inhibitor of UptakeDA (GBR 12909), stimulus-evoked DA overflow is selectively protected against the effect of 6-OHDA. Under these circumstances, nerve stimulation increases glomerular filtration and excretion of water, but not of sodium. These effects are abolished by DA1 receptor blockade. 5. These data indicate that DA is released from intrarenal dopaminergic nerve terminals in vivo, both in response to direct nerve stimulation and tonically under conditions of volume expansion. The main effects of dopaminergic nerve activation are juxtaglomerular vasodilatation and inhibition of distal tubular water reabsorption.